1 Christopher J. Sweeney, MBBS, Dana-Farber Cancer Institute, Boston, MA; Richard De Abreu Lourenco, PhD, University of Technology Sydney, Sydney, NSW, Australia; Anis A. Hamid, MBBS, Dana-Farber Cancer Institute, Boston, MA; and Marc Buyse, ScD, International Drug Development Institute, Louvain-la-Neuve, Belgium.